Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

BACKGROUND: Nearly all anti-PD-1 antibodies are of the IgG4 isotype, and thus possess residual FcR effector functions. Such anti-PD-1 antibodies are also associated with immune tolerance and escape due to instability of the CH3 domain and Fc-Fc interaction. In this trial, we examined the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Zhou, Keshu, Jin, Chuan, Qian, Zhengzi, Hou, Ming, Fan, Lei, Li, Fei, Ding, Kaiyang, Zhou, Hui, Li, Xiaoling, Chen, Bing, Sun, Xiuhua, Song, Xianmin, Jiang, Ming, Zhang, Qingyuan, Liu, Lihong, Yu, Guohua, Hu, Yu, Zhao, Zheng, Liu, Ligen, Xue, Hongwei, Luo, Jun, He, Bai, Jin, Xiaoping, Zhao, Min, Li, Baiyong, Xia, Yu, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301139/
https://www.ncbi.nlm.nih.gov/pubmed/35875118
http://dx.doi.org/10.3389/fonc.2022.925236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301139/
https://www.ncbi.nlm.nih.gov/pubmed/35875118
http://dx.doi.org/10.3389/fonc.2022.925236

Ejemplares similares